TRANSFORMATIVE CELL-BASED THERAPIES
TO TREAT KIDNEY DISEASE PATIENTS
TO TREAT KIDNEY DISEASE PATIENTS
TRANSFORMATIVE CELL-BASED THERAPIES
TO TREAT KIDNEY DISEASE PATIENTS
TO TREAT KIDNEY DISEASE PATIENTS
ABOUT
LIVEKIDNEY.BIO is a clinical stage biotech company developing a proprietary delivery platform, based on biodegradable hydrogel formulations for cell therapies.
These medical moieties aim to prevent the progression of kidney disease towards kidney failure, as well as to improve related comorbidities such as diabetes, hypertension and obesity, thereby allowing kidney patients to live longer and healthier lives.
Our solution could significantly alleviate the growing social burden and costs of kidney disease to patients and public healthcare organizations.
OUR PIPELINE:
We develop proprietary pharma grade injectable hydrogel formulations to deliver Umbilical Cord–derived Mesenchymal Stromal Cells (UC-MSCs) to ameliorate the kidney function of advanced Chronic Kidney Disease (CKD) and Lupus Nephritis (LN) patients.
Our pipeline offers a potentially safe and effective therapeutic path via a unique regional route of administration.
In vitro studies > Animal studies > Clinical studies
* Perirenal adipose tissue (PRAT) is a fat pad that surrounds the kidneys. PRAT functions: produce and release hormones and compounds which regulate renal and systemic metabolic functions.
CKD MARKET
- Over 850 million (M) patients worldwide (WW), a devastating progressive disease with no cure
- Over 4M patients WW on dialysis with only one-third surviving 5 years
- >$130 billion annual expenses on CKD care in the US
- Patients reaching End-Stage Renal Disease (ESRD) are left with no cure and no hope
- There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation)
CKD MARKET
- Over 850 million (M) patients worldwide (WW), a devastating progressive disease with no cure
- Over 4M patients WW on dialysis with only one-third surviving 5 years
- >$130 billion annual expenses on CKD care in the US
- Patients reaching End-Stage Renal Disease (ESRD) are left with no cure and no hope
- There is an increasing unmet medical need for safe and effective treatments that can improve kidney function in advanced kidney disease patients before they require Renal Replacement Therapy (dialysis or transplantation)
LUPUS NEPHRITIS MARKET
- Lupus Nephritis (LN) is a particularly severe kidney disease manifestation of Lupus, occurring in 60% of cases and correlating with a higher mortality rate.
- 5 million Lupus patients worldwide; chronic autoimmune disease in which the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body, including the kidneys, skin, joints and other organs. Symptoms can vary widely and may include fatigue, joint pain, rashes, and kidney problems.
- Lupus predominantly affects women of childbearing age, with 10-fold higher prevalence in females.
- Lupus market is estimated around $1billion with an expected 5.6% annual growth rate.
- The main goal of LN management is to avoid ESRD.
MANAGEMENT TEAM
Dr. Alon Yaar, DVM, MBA: CEO
Former CEO/COO of NeuroDerm (NASDAQ:NDRM) acquired by Mitsubishi Tanabe in 2017 in a $1.2 billion deal.
Dr. Masha Simanovsky, Ph.D.: Head of R&D
Expert in cell therapy and Extracellular Vesicles.
Dr. Shimon Amselem, Ph.D.: Head of CMC and Formulations
Expert in implantable biodegradable polymers. Significant contributions to five approvals by the FDA and four IND in Phase II/III clinical trials.
Avraham Hermon, MA: Head of IP
Israeli Patent Attorney and a US Patent Agent. Former Senior Manager at Teva Pharmaceutical Industries.
Dr. Nadya Lisovoder, MD: Clinical Leader
Regulatory expert and a clinical adviser with vast experience in clinical studies in the pharma industry.
ADVISORY BOARD
Prof. Chaim Putterman
Professor of Medicine & Immunology at the Albert Einstein College of Medicine
Prof. Lilach O. Lerman
Professor of Medicine at The Renovascular Disease Research Laboratory, Mayo Clinic
Prof. Gary Gilkeson
Professor of Medicine, Associate Dean for Faculty Affairs and Faculty Development, Medical University of South Carolina
Eli Gelman
Chairman of the Board, Amdocs Limited, Chairman of the Executive Council of Tel Aviv University
TO LEARN MORE, OR PARTNER WITH LIVEKIDNEY,
CONTACT US TODAY!
CONTACT
STRATEGIC PARTNERSHIPS
Albert Einstein College of Medicine
Mayo Clinic
Medical University of South Carolina
Mayo Clinic
Medical University of South Carolina
ADVANCED CELL THERAPY
Aiming to prevent the progression of Chronic Kidney Disease.
Stage: clinical stage, Phase II: 2024
Stage: clinical stage, Phase II: 2024
